Colorectal signet ring cell carcinoma: advancing research in a rare cancer

Future OncologyVol. 16, No. 17 CommentaryColorectal signet ring cell carcinoma: advancing research in a rare cancerValeria Barresi & Corrado PedrazzaniValeria Barresi*Author for correspondence: E-mail Address: valeria.barresi@univr.itDepartment of Diagnostics and Public Health, University of Verona, Verona, Italy & Corrado PedrazzaniDepartment of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Unit of General and Hepatobiliary Surgery, University of Verona, Verona, ItalyPublished Online:30 Apr 2020https://doi.org/10.2217/fon-2020-0242AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: colorectal carcinomaepithelial mesenchymal transitionmolecular subtypeorganoidprognosissignet ringtherapyReferences1. Remo A, Fassan M, Vanoli A et al. Morphology and molecular features of rare colorectal carcinoma histotypes. Cancers 11(7), 1–26 (2019).Crossref, Google Scholar2. Nagtegaal ID, Arends MJ, Salto-Tellez M. Colorectal adenocarcinoma. In: In WHO Classification of Tumor of the Digestive system. IARCC Press I, Lyon, France, 177–187 (2020).Google Scholar3. Barresi V, Reggiani Bonetti L, Domati F, Baron L. Prognostic relevance of histopathological features in signet ring cell carcinoma of the colorectum. Virchows Arch. 469(3), 267–275 (2016).Crossref, Medline, Google Scholar4. Hugen N, Van De Velde CJ, De Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann. Oncol. 25(3), 651–657 (2014).Crossref, Medline, CAS, Google Scholar5. Nitsche U, Zimmermann A, Spath C et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann. Surg. 258(5), 775–782 (2013).Crossref, Medline, Google Scholar6. Shi T, Huang M, Han D et al. Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: a surveillance, epidemiology and end results database analysis. Cancer Med. 8(4), 1930–1940 (2019).Crossref, Medline, Google Scholar7. Alvi MA, Loughrey MB, Dunne P et al. Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br. J. Cancer 117(2), 203–209 (2017).Crossref, Medline, CAS, Google Scholar8. Nam JY, Oh BY, Hong HK et al. Molecular characterization of colorectal signet-ring cell carcinoma using whole-exome and RNA Sequencing. Transl. Oncol. 11(4), 836–844 (2018).Crossref, Medline, Google Scholar9. Bellan A, Cappellesso R, Lo Mele M et al. Early signet ring cell carcinoma arising from colonic adenoma: the molecular profiling supports the adenoma-carcinoma sequence. Hum. Pathol. 50, 183–186 (2016).Crossref, Medline, CAS, Google Scholar10. Wu X, Lin H, Li S. Prognoses of different pathological subtypes of colorectal cancer at different stages: a population-based retrospective cohort study. BMC Gastroenterol. 19(1), 164 (2019).Crossref, Medline, Google Scholar11. Ackermann CJ, Guller U, Jochum W, Schmied BM, Warschkow R. The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis. Int. J. Colorectal Dis. 33(9), 1183–1193 (2018).Crossref, Medline, Google Scholar12. Hugen N, Verhoeven RH, Lemmens VE et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int. J. Cancer 136(2), 333–339 (2015).Crossref, Medline, CAS, Google Scholar13. Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408–3419 (2004).Crossref, Medline, Google Scholar14. Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. J. Oncol. Pract. 13(4), 233–241 (2017).Crossref, Medline, Google Scholar15. Labianca R, Nordlinger B, Beretta GD et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6), vi64–vi72 (2013).Crossref, Medline, Google Scholar16. National Comprehensive Cancer Network. Colon cancer (2018). www.nccn.org/professionals/physician_gls/default.aspxGoogle Scholar17. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21(11), 1350–1356 (2015).Crossref, Medline, CAS, Google Scholar18. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 5(1), 16–18 (2015).Crossref, Medline, CAS, Google Scholar19. Li Y, Wang R, Huang D et al. A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application. Carcinogenesis doi:10.1093/carcin/bgz178 (2019) (Epub ahead of print).Crossref, Google ScholarFiguresReferencesRelatedDetailsCited ByApplications of human organoids in the personalized treatment for digestive diseases27 September 2022 | Signal Transduction and Targeted Therapy, Vol. 7, No. 1Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets26 May 2022 | Oncogene, Vol. 41, No. 26 Vol. 16, No. 17 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 172 times History Received 30 March 2020 Accepted 8 April 2020 Published online 30 April 2020 Published in print June 2020 Information© 2020 Future Medicine LtdKeywordscolorectal carcinomaepithelial mesenchymal transitionmolecular subtypeorganoidprognosissignet ringtherapyFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.PDF download